The first diagnostic framework for measuring individual biological sensitivity to environmental mold exposure.
🔬 Pilot Phase — 2026We can measure mold in buildings with precision. What we cannot do is measure what mold does to a specific person. Two people can live in the same moldy home — one gets devastatingly ill, the other feels nothing.
Medicine has no standardized tool to answer this question. Patients are told their labs are normal. Buildings are remediated and people still feel sick. The missing piece isn't environmental data — it's individual biological response data.
The Mold Reactivity Index combines three independent biological signals into a composite score — measuring the immune system, the autonomic nervous system, and subjective symptom response together for the first time.
Cytokine response from peripheral blood — measuring how the immune system reacts to standardized antigenic challenge at the cellular level.
Heart rate variability during controlled environmental challenge — capturing nervous system stress response that standard labs miss entirely.
Structured self-reported symptom scoring across eight domains before, during, and after challenge — giving subjective experience a quantifiable form.
These three signals are combined into a composite MRI score (0–10) and a phenotype classification — Normal, Moderate, or Hyper-Reactive — giving clinicians and researchers a standardized language for individual sensitivity that doesn't currently exist.
The Environmental Health Typology System plots each individual on a two-axis framework: their biological sensitivity (MRI score) against their environmental burden (exposure load). This creates four clinically distinct quadrants that finally explain why the same environment affects people so differently.
High environmental load, low biological reactivity. Exposed but not reacting. Monitoring recommended.
High load + high reactivity. The classic mold illness presentation. Immediate remediation and treatment.
Low load, low reactivity. Healthy baseline. Reference population for research.
Low load, high reactivity. Nervous system imprint from prior exposure. Environment is clean — the person needs treatment.
Quadrant D is perhaps the most important — it identifies patients who continue to suffer after remediation, explaining the mystery of why "they fixed the building but I still feel sick."
Alaska UpLift LLC is conducting a private 10-person pilot study to generate the first real-world validation data for the MRI framework. The pilot uses commercial clinical laboratories — no institutional dependency, no multi-year university timeline.
Provisional patent application filed with USPTO covering the MRI scoring methodology and EHTS framework.
Custom data collection and scoring platform built and deployed. Participant enrollment in progress.
10 participants across exposure history profiles. HRV, cytokine panels, symptom scoring.
NIEHS Phase I application targeting ~$300K for expanded validation study.
International patent protection with pilot data as supporting evidence.
A validated individual sensitivity diagnostic opens doors that don't currently exist:
Gives physicians a standardized tool to diagnose and monitor mold-reactive patients — ending the era of "your labs are normal."
Objective data for litigation, property disclosure, and occupational health claims. A new evidentiary standard.
First standardized dataset linking environmental exposure to individual biological response — a new category of health data.
Answers the question patients have been asking for decades: "Am I actually reactive, or is it something else?"
We're actively building research partnerships, clinical relationships, and investor conversations as we move through the pilot phase.